The Pharmaceutical Market: Mexico

Date: January 31, 2013
Pages: 165
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PA9CC39E4FAEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Mexico
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MEXICO

The improving regulatory environment and the increasing foreign direct investment make Mexico's pharmaceutical market more attractive to multinational drugmakers. We project an increase in government healthcare spending to further boost the number of procedures and expand access to medicines in its national health insurance programme. However, the potential deceleration of the country's macroeconomic growth may dampen the country's pharmaceutical market prospects. Generic drug competition and counterfeit medicines are also key concerns for multinationals pharmaceutical companies.

Headline Expenditure Projections

Pharmaceuticals: MXN161.45bn (US$12.99bn) in 2011 to MXN175.82bn (US$13.47bn) in 2012; +8.9% in local currency terms and +3.7% in US dollar terms. Forecasts increase from Q4 12 due to macroeconomic factors.

Healthcare: MXN872.57bn (US$70.21bn) in 2011 to MXN951.98bn (US$72.95bn) in 2012; +9.1% in local currency terms and +3.9 % in US dollar terms. F orecasts increase from Q4 12 due to macroeconomic factors.

Medical devices: MXN52.05bn (US$4.19bn) in 2011 to MXN57.85bn (US$4.43bn) in 2012; +11.1% in local currency terms and +5.9% in US dollar terms. F orecasts increase from Q4 12 due to macroeconomic factors.


Risk/Reward Rating: The Pharmaceutical and Healthcare Risk/Reward Rating (RRR) in Q113 for Mexico remains the same (58.4) as in Q412. Mexico still ranks the fourth out of the 17 Americas markets surveyed in our proprietary regional RRR rating system above Brazil, indicating a more optimistic outlook for Mexican market.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      Mexico Pharmaceuticals And Healthcare Industry SWOT
      Mexico Political SWOT
      Mexico Economic SWOT
      Mexico Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

      Table: Americas Pharmaceutical And Healthcare Risk/Reward Ratings, Q113
      Rewards
      Risks

MEXICO – MARKET SUMMARY

REGULATORY REGIME

      Marketing Registration
      Table: Legal Pharmaceutical Registration Requirements
      Table: Legal Pharmaceutical Registration Requirements
      Import Regulation
      Table: Import Fees
      Table: Registration Renewal Requirements
      Release Of Manufacturing Requirements
      Regulation Of Antibiotics
      Post-Marketing
      Advertising
  Biologics And Biosimilar Guideline
      Research & Development
      Table: NOM-177-SSA1-1998’s Generic Tests
      Intellectual Property Rights
      Intellectual Property Environment
      IP Shortcomings
      Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights
      Counterfeit Drugs
      Pricing & Reimbursement
      Reimbursement
      Pricing Issues
      Pricing Developments
      Reimbursement Issues
      Other Regulatory Developments

INDUSTRY TRENDS AND DEVELOPMENTS

      Epidemiology
      Non-Communicable Diseases
      Healthcare Sector
      Health Insurance
      Healthcare Sector Funding
      Medical Tourism
      Research & Development
    Clinical Trials
    Table: Clinical Trial Regulation In Mexico
    Table: Clinical Studies, 2003-09
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
    Key Growth Drivers – Industry
    Table: Healthcare Expenditure Indicators 2008-2016
    Table: Healthcare Governmental Indicators 2008-2016
    Table: Healthcare Private Indicators 2008-2016

KEY GROWTH DRIVERS – MACROECONOMIC

    Table: Mexico Macro Indicators
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators 2008-2016
    Generic Drug Market Forecast
    Table: Generic Drug Sales Indicators, 2008-2016
    Associations
    Table: Members of AMEGI, 2011
    Members of ANAFAM, 2011
    OTC Medicine Market Forecast
    Table: OTC Medicine Sales Indicators 2008-2016
    Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators 2008-2016
    Medical Device Market Forecast
    Table: Medical Devices Sales Indicators, 2008-2016
    Other Healthcare Data
    Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

    Pharmaceuticals Industry
    Pharmaceutical Company Activity
    Foreign Competition
    Table: Members of AFAMELA, 2012
    Table: Members of AMIIF, 2012
    Table: Members of CANIFARMA, 2012
    Table: AstraZeneca’s Sales, 2005-10
    Pharmaceutical Distribution Sector
    Wholesale
    DIPROFAR
    Grupo Casa Saba
    Marzam
    NADRO
    Pharmaceuticals Retail Sector
    Table: IMSS Pharmacies, 2000-11
    Table: IMSS Financial Indicators, 2000-11 (MXNmn)
    Table: Leading Pharmaceutical Suppliers to IMSS, 2010-12 (MXNmn)
      Table: IMSS Expenditure on Disease & Maternity Insurance by State, 2011 (MXNmn)
      ISSSTE
      Table: ISSSTE’s Pharmaceutical Expenditure, 2006-12
      Seguro Popular
      Table: SPSS Budget, 2004-11 (MXNmn)
      Table: FPGC Disease Groups, 2011
      Table: FPGC Cases & Cost By Disease, Authorised In 2011, Validated And Paid By December 31 2011
      Associations of Independent Pharmacies
      Table: Members of ANADIM, 2012
      Members of ANEFAR, 2012
      Pharmacy Chains
      Farmacias del Ahorro
      Farmacias Benavides
      Table: Farmacias Benavides’ Key Indicators, 2003-11
      Farmacias El Fenix
      Corporativo Fragua
      Table: Corporativo Fragua’s Key Indicators, 2005-11
      Farmacias Similares
      Walmart

COMPANY PROFILES

  Local Company Profiles
      Genomma Labs
  Multinational Companies
      Pfizer
      GlaxoSmithKline (GSK)
      Sanofi
      Eli Lilly
      Bristol-Myers Squibb
      Novartis
      Bayer
      Boehringer Ingelheim
      Merck KGaA
      Roche Syntex

DEMOGRAPHIC OUTLOOK

      Mexico - Population By Age Group
      Mexico - Population By Age Group
      Mexico - Key Population Ratios
      Mexico - Rural and Urban Population

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceutical Industry Forecasts
      Pharmaceutical Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceutical Risk/Reward Indicators
      Weighting
      Table: Weighting Of Components
      Sources
Skip to top


The Pharmaceutical Market: USA US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Italy US$ 1,295.00 Jan, 2013 · 76 pages
The Pharmaceutical Market: Japan US$ 1,295.00 Jan, 2013 · 99 pages

Ask Your Question

The Pharmaceutical Market: Mexico
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: